氯巴占在癲癇治療中的研究進展_Journal of Epilepsy

Authors：

翟菲菲 ,  盧強

中國醫學科學院·北京協和醫院神經內科（北京 100730）;

Corresponding?author：

盧強, Email: luqiang@pumch.cn

Keywords：

DOI：

10.7507/2096-0247.202201007

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 翟菲菲, 盧強. 氯巴占在癲癇治療中的研究進展. Journal of Epilepsy, 2022, 8(2): 133-137. doi: 10.7507/2096-0247.202201007 Copy

1.	Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
2.	Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 2019, 18(5): 459-480.
3.	Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia, 2018, 59(12): 2179-2193.
4.	Ng Y, Collins S D. Clobazam. Neurotherapeutics, 2007, 4(1): 138-144.
5.	Humayun MJ, Samanta D, Carson RP. Clobazam. //StatPearls. Treasure Island (FL): StatPearls Publishing, 2021.
6.	FDA approves onfi for seizures associated with lennox-gastaut syndrome[EB/OL]. Drugs. com, [2022-01-02]. https://www.drugs.com/newdrugs/fda-approves-onfi-seizures-associated-lennox-gastaut-syndrome-2921.html.
7.	唐芯, 向上, 肖農. 氯巴占輔助治療Lennox-Gastaut綜合征的研究進展. 中華神經科雜志, 2015, 47, (12): 1110-1112.
8.	Sankar R. GABAA receptor physiology and its relationship to the mechanism of action of the 1, 5-benzodiazepine clobazam. CNS Drugs, 2012, 26(3): 229-244.
9.	Hashi S, Yano I, Shibata M, et al. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. European Journal of Clinical Pharmacology, 2015, 71(1): 51-58.
10.	Saruwatari J, Ogusu N, Shimomasuda M, et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and n-desmethylclobazam in japanese patients with epilepsy. Therapeutic Drug Monitoring, 2014, 36(3): 302-309.
11.	Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia, 2009, 50(5): 1158-1166.
12.	Ng Y T, Conry J A, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology, 2011, 77(15): 1473-1481.
13.	Conry JA, Ng Y, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop seizure and total seizure improvements over 3 years. Epilepsia, 2014, 55(4): 558-567.
14.	Gidal BE, Wechsler RT, Sankar R, et al. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology, 2016, 87(17): 1806-1812.
15.	Cramer JA, Sapin C, Fran?ois C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurologica Scandinavica, 2013, 128(2): 91-99.
16.	Gunning B, Mazurkiewicz-Be?dzińska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurologica Scandinavica, 2021, 143(2): 154-163.
17.	Lamb A, Dawoud D, Dent R, et al. Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes. The Lancet Neurology, 2020, 19(4): 290-291.
18.	Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the canadian experience. Epilepsia, 1991, 32(1): 11.
19.	Jamil A, Levinson N, Gelfand M, et al. Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy. Neurology, 2021, 11(5): e669-e676.
20.	Kalra V, Seth R, Mishra D, et al. Clobazam in refractory childhood epilepsy. The Indian Journal of Pediatrics, 2010, 77(3): 263-266.
21.	Bresnahan R, Martin-McGill KJ, Williamson J, et al. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews, 2019, 10(10): CD004154.
22.	Montenegro MA, Cendes F, Noronha ALA, et al. Efficacy of Clobazam as Add-On Therapy in Patients with Refractory Partial Epilepsy. Epilepsia, 2001, 42(4): 539-542.
23.	Buchanan N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. Journal of the Royal Society of Medicine, 1993, 86(7): 378-380.
24.	Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia, 1987, 28(5): 495-506.
25.	Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Canadian Journal of Neurological Sciences, 1990, 17(3): 317-319.
26.	Sivakumar S, Ibrahim M, Parker D, et al. Clobazam: an effective add-on therapy in refractory status epilepticus. Epilepsia, 2015, 56(6): e83-e89.
27.	Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia, 1998, 39(9): 952-959.
28.	Arya R, Giridharan N, Anand V, et al. Clobazam monotherapy for focal or generalized seizures. Cochrane epilepsy group. Cochrane Database of Systematic Reviews, 2018, 2018(7).
29.	Dulac O, Figueroa D, Rey E, et al. Monotherapy with clobazam in epilepsies in children. Presse Medicale, 1983, 12(17): 1067-1069.
30.	Mehndiratta MM, Krishnamurthy M, Rajesh KN, et al. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure, 2003, 12(4): 226-228.
31.	Clobazam adjunctive treatment of adults with refractory focal epilepsy[EB/OL]. [2022-01-02]. https://clinicaltrials.gov/ct2/show/record/NCT02726919.
32.	Clobazam use in epilepsia partialis continua—pilot study[EB/OL]. [2022-01-02] .https://clinicaltrials.gov/ct2/show/NCT02134366.
33.	Clobazam Tablets—FDA prescribing information, side effects and uses[EB/OL]. Drugs.com, [2022-01-02]. https://www.drugs.com/pro/clobazam-tablets.html.
34.	Thomas SV, Jose M, Divakaran S, et al. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia, 2017, 58(2): 274-281.
35.	FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes[EB/OL]. FDA(2019-06-21)[2022-01-02]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-serious-skin-reactions-anti-seizure-drug-onfi-clobazam-and.
36.	Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neuroscience & Therapeutics, 2015, 21(7): 543-548.

1. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
2. Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 2019, 18(5): 459-480.
3. Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia, 2018, 59(12): 2179-2193.
4. Ng Y, Collins S D. Clobazam. Neurotherapeutics, 2007, 4(1): 138-144.
5. Humayun MJ, Samanta D, Carson RP. Clobazam. //StatPearls. Treasure Island (FL): StatPearls Publishing, 2021.
6. FDA approves onfi for seizures associated with lennox-gastaut syndrome[EB/OL]. Drugs. com, [2022-01-02]. https://www.drugs.com/newdrugs/fda-approves-onfi-seizures-associated-lennox-gastaut-syndrome-2921.html.
7. 唐芯, 向上, 肖農. 氯巴占輔助治療Lennox-Gastaut綜合征的研究進展. 中華神經科雜志, 2015, 47, (12): 1110-1112.
8. Sankar R. GABAA receptor physiology and its relationship to the mechanism of action of the 1, 5-benzodiazepine clobazam. CNS Drugs, 2012, 26(3): 229-244.
9. Hashi S, Yano I, Shibata M, et al. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. European Journal of Clinical Pharmacology, 2015, 71(1): 51-58.
10. Saruwatari J, Ogusu N, Shimomasuda M, et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and n-desmethylclobazam in japanese patients with epilepsy. Therapeutic Drug Monitoring, 2014, 36(3): 302-309.
11. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia, 2009, 50(5): 1158-1166.
12. Ng Y T, Conry J A, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology, 2011, 77(15): 1473-1481.
13. Conry JA, Ng Y, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop seizure and total seizure improvements over 3 years. Epilepsia, 2014, 55(4): 558-567.
14. Gidal BE, Wechsler RT, Sankar R, et al. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology, 2016, 87(17): 1806-1812.
15. Cramer JA, Sapin C, Fran?ois C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurologica Scandinavica, 2013, 128(2): 91-99.
16. Gunning B, Mazurkiewicz-Be?dzińska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurologica Scandinavica, 2021, 143(2): 154-163.
17. Lamb A, Dawoud D, Dent R, et al. Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes. The Lancet Neurology, 2020, 19(4): 290-291.
18. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the canadian experience. Epilepsia, 1991, 32(1): 11.
19. Jamil A, Levinson N, Gelfand M, et al. Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy. Neurology, 2021, 11(5): e669-e676.
20. Kalra V, Seth R, Mishra D, et al. Clobazam in refractory childhood epilepsy. The Indian Journal of Pediatrics, 2010, 77(3): 263-266.
21. Bresnahan R, Martin-McGill KJ, Williamson J, et al. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews, 2019, 10(10): CD004154.
22. Montenegro MA, Cendes F, Noronha ALA, et al. Efficacy of Clobazam as Add-On Therapy in Patients with Refractory Partial Epilepsy. Epilepsia, 2001, 42(4): 539-542.
23. Buchanan N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. Journal of the Royal Society of Medicine, 1993, 86(7): 378-380.
24. Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia, 1987, 28(5): 495-506.
25. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Canadian Journal of Neurological Sciences, 1990, 17(3): 317-319.
26. Sivakumar S, Ibrahim M, Parker D, et al. Clobazam: an effective add-on therapy in refractory status epilepticus. Epilepsia, 2015, 56(6): e83-e89.
27. Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia, 1998, 39(9): 952-959.
28. Arya R, Giridharan N, Anand V, et al. Clobazam monotherapy for focal or generalized seizures. Cochrane epilepsy group. Cochrane Database of Systematic Reviews, 2018, 2018(7).
29. Dulac O, Figueroa D, Rey E, et al. Monotherapy with clobazam in epilepsies in children. Presse Medicale, 1983, 12(17): 1067-1069.
30. Mehndiratta MM, Krishnamurthy M, Rajesh KN, et al. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure, 2003, 12(4): 226-228.
31. Clobazam adjunctive treatment of adults with refractory focal epilepsy[EB/OL]. [2022-01-02]. https://clinicaltrials.gov/ct2/show/record/NCT02726919.
32. Clobazam use in epilepsia partialis continua—pilot study[EB/OL]. [2022-01-02] .https://clinicaltrials.gov/ct2/show/NCT02134366.
33. Clobazam Tablets—FDA prescribing information, side effects and uses[EB/OL]. Drugs.com, [2022-01-02]. https://www.drugs.com/pro/clobazam-tablets.html.
34. Thomas SV, Jose M, Divakaran S, et al. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia, 2017, 58(2): 274-281.
35. FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes[EB/OL]. FDA(2019-06-21)[2022-01-02]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-serious-skin-reactions-anti-seizure-drug-onfi-clobazam-and.
36. Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neuroscience & Therapeutics, 2015, 21(7): 543-548.

Previous Article
Expression analysis and bioinformatics prediction of circrnas in peripheral blood mononuclear cells of epilepsy patients
Next Article
穿透征（Transmantle sign）的磁共振成像及其特征

Journal of Epilepsy

氯巴占在癲癇治療中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content